BioMarin Pharma BMRN

HealthcareMarket cap $15B2 connections

BioMarin specializes in rare genetic diseases - its Voxzogo treats achondroplasia (the most common form of dwarfism) and Roctavian is the first gene therapy for hemophilia A approved in the US. Rare disease drugs command extraordinary prices due to small patient populations and lack of alternatives.

Explore BioMarin Pharma on the interactive map Relationship timeline Find a path to another company

Suppliers 1

Companies that sell to BioMarin Pharma

Thermo FisherHealthcare · $220BThermo Fisher supplies BioMarin gene therapy tools

Competitors 1

Companies it competes with

Ultragenyx PharmaHealthcare · $5BRare disease therapies

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show BioMarin Pharma's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=BMRN" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="BioMarin Pharma on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.